SUO 2022: Using Biomarkers and Somatic Testing to Guide Treatment Choice urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
SHARE
ASCO GU 2020: Next-Generation Sequencing (NGS) of Tumor Tissue from >4000 Men with mCRPC: The PROfound Phase III Study Experience
San Francisco, California (UroToday.com) Metastatic castration-resistant prostate cancer (mCRPC) is a molecularly heterogeneous disease, with between 20 and 25% of patients with mCRPC harboring deleterious alterations in DNA damage repair genes, including those with direct or indirect roles in homologous recombination repair (HRR). These gene alterations, of which
BRCA1,
BRCA2, and
ATM are the most well-characterized, can confer sensitivity to PARP inhibition. The PROfound study showed that olaparib provides a statistically significant improvement in radiographic progression-free survival versus physician’s choice of enzalutamide or abiraterone in mCRPC patients with alterations in genes with a direct or indirect role in the HRR pathway.